This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/chemspider/
n13http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/chebi/
n17http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/wikipedia/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/pdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/pubchem-compound/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/pubchem-substance/
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB02901/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB02901
rdf:type
n3:Drug
n3:description
A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid. [PubChem]
n3:group
illicit experimental
owl:sameAs
n6:DB02901 n16:DB02901
dcterms:title
Dihydrotestosterone
adms:identifier
n8:C03917 n9:DHT n10:14 n11:DB02901 n12:18161 n13:16330 n14:15 n15:46506828 n17:Dihydrotestosterone
n3:synonym
17beta-Hydroxyandrostan-3-one (5a,17b)-17-Hydroxyandrostan-3-one Stanaprol 17beta-Hydroxy-5alpha-androstane-3-one 5.alpha.-Dihydrotestosterone 5alpha dihydrotestosterone Androstan-17beta-ol-3-one 5a-Dihydrotestosterone Androstan-17b-ol-3-one 17beta-Hydroxy-5alpha-androstan-3-one Anaboleen Androlone Androstanolone 4-Dihydrotestosterone 5alpha-Dihydrotestosterone (5alpha,17beta)-17-hydroxyandrostan-3-one Stanolone
n3:toxicity
Oral LD<sub>50</sub> in rat is 7060 mg/kg. Oral LD<sub>50</sub> in mouse is 3450 mg/kg.
n3:synthesisReference
A. Glenn Braswell, Aftab J. Ahmed, "Composition for inhibiting production of dihydrotestosterone to treat benign prostate hyperplasia." U.S. Patent US6264996, issued October, 1996.
n19:hasConcept
n20:M0020414
n3:IUPAC-Name
n4:271B6376-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B637C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B637B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6378-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6379-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B637A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6374-363D-11E5-9242-09173F13E4C5 n4:271B638C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6375-363D-11E5-9242-09173F13E4C5 n4:271B6372-363D-11E5-9242-09173F13E4C5 n4:271B638E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6373-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6382-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6383-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B637D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B637E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6380-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B637F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6381-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is very low (0-2%) following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
521-18-6
n3:category
n3:Bioavailability
n4:271B6388-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B638A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B638B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B638D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6387-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6386-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6389-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6377-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6384-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6385-363D-11E5-9242-09173F13E4C5